Trial Profile
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYSTROKE
- 07 Feb 2023 Planned End Date changed from 1 Jul 2026 to 1 Jul 2029.
- 07 Feb 2023 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2027.
- 29 Feb 2020 Results (n=7) evaluating the safety and efficacy of stereotactic body radiation (SBRT) re-irradiation (reRT) plus concurrent and adjuvant P in patients with R/new second primary (NSP) HNSCC, presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium